Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
about
Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesionsLong term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesionsBarrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesisEffect of medical and surgical treatment of Barrett's metaplasiaRisk factors and chemoprevention in Barrett's esophagus--an update.Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysisChemoprevention of esophageal adenocarcinomaThe incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.Acid-suppressive Medications and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus(Gut 2014;63:1229-1237).American Gastroenterological Association technical review on the management of Barrett's esophagusMicrobiome and potential targets for chemoprevention of esophageal adenocarcinoma.Current status and future perspectives on the etiology of esophageal adenocarcinoma.Barrett's Esophagus: Emerging Knowledge and Management StrategiesBarrett esophagus: what a mouse model can teach us about human diseaseColumnar lined (Barrett's) esophagus: future perspectives.Diagnosis and management of Barrett's esophagus.Trajectories of endoscopic Barrett esophagus: Chronological changes in a community-based cohort.Medication usage and the risk of neoplasia in patients with Barrett's esophagus.Definition of Barrett's esophagus: time for a rethink--is intestinal metaplasia dead?Managing Barrett's esophagus with radiofrequency ablationBarrett's esophagus: proton pump inhibitors and chemoprevention I.Role of acid suppression in the development and progression of dysplasia in patients with Barrett's esophagus.Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development.Carcinogenesis of Barrett's esophagus: a review of the clinical literature.Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.One year treatment of Barrett's oesophagus with proton pump inhibitors (a multi-center study).Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.Barrett's esophagus: endoscopic treatments II.Which is the best choice for gastroesophageal disorders: Melatonin or proton pump inhibitors?Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study.Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
P2860
Q24187480-5993ED15-1F66-4D73-B4BF-30978865DDC8Q24202377-A36C5613-3675-4007-82CD-DA3B544AAC9EQ24602426-8B44DB63-67A6-44BA-9F7A-F7F247C37801Q34063700-41E482AE-0122-45D2-AE95-650DE9739626Q34201351-CAAD9E77-C145-4107-8722-1E955730F9A9Q34352867-4A8AFD7E-79B7-493B-9B47-4BE6D1E84CCDQ34408890-73BEDDF2-ED67-4314-9ADB-AD03BDDE5B38Q34786281-B712AA5E-F3AF-438B-A3DF-F4989E743B85Q35430468-3FA89EB0-6762-4E10-BA40-88D6DEDB8B7AQ35673305-13B5C711-B116-403A-B1B9-9A4342FBC1C5Q35954977-F6AFCAB3-E58B-40AF-9E07-E93CA006FBE0Q35972032-2B58C0D3-FDBA-4529-A737-0619A4D478D7Q36014649-193CD1C7-57B7-4992-91B2-7BEFE9CA1080Q36556299-3D70341C-6E4A-4EDA-9983-1D9B905F61E5Q36940066-453B10D1-9ACB-477F-A1CC-7C7E05AEF0D5Q37055792-20EE0D69-7A82-4C63-8DD8-D21BBD5630CCQ37267289-82943597-5C08-47C2-A8BB-2650D946F8B8Q37463812-E0A5C0A8-942C-4D40-8FD4-052F6BF71496Q37558153-E00B6033-3BF2-4A11-A6A5-FE020EB75BA3Q37609156-7ABCF4F8-A982-4B61-847D-1C04EC0CAD77Q37939281-2F87A5FF-606F-4B74-A36C-02ACFA73BB3AQ37957710-857BB39E-3E14-4CF0-A282-CA0D665F00C8Q37967701-70404D4A-9D9F-4195-AD8D-A2756FDB0FD9Q38042937-8CB2EC2C-827C-4A07-B89F-415B7C4CCACEQ38548565-40D4064C-0607-4E8A-A058-03F7B802359AQ38631128-9F6C7E57-8DBA-4A86-8A20-1F57E0159DAFQ39194800-0237C134-E152-4ED4-B828-D3F15B5B2F89Q39234055-6CD6FB23-92A8-43A6-9FB8-468C247B745BQ39992700-91F483ED-FEF2-45B6-9E01-C44926616EE1Q42553733-A9815B89-0F80-46C8-A546-5BCA15258801Q43960201-C74CC4E0-3301-4432-A683-ACD796B4EACAQ46115635-0F9F7234-273E-4ABA-9A2E-CBF8DCFC3B93
P2860
Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Continuous treatment of Barret ...... gression and cancer incidence.
@ast
Continuous treatment of Barret ...... gression and cancer incidence.
@en
Continuous treatment of Barret ...... gression and cancer incidence.
@nl
type
label
Continuous treatment of Barret ...... gression and cancer incidence.
@ast
Continuous treatment of Barret ...... gression and cancer incidence.
@en
Continuous treatment of Barret ...... gression and cancer incidence.
@nl
prefLabel
Continuous treatment of Barret ...... gression and cancer incidence.
@ast
Continuous treatment of Barret ...... gression and cancer incidence.
@en
Continuous treatment of Barret ...... gression and cancer incidence.
@nl
P2093
P2860
P1476
Continuous treatment of Barret ...... egression and cancer incidence
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2006.02825.X
P407
P577
2006-03-01T00:00:00Z